novo nordisk amycretin

News

Obesity, Novo Nordisk and Amycretin

Novo Nordisk Fast-Tracks Amycretin to Phase 3 for Obesity Treatment

Novo Nordisk (NYSE:NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance directly to Phase 3 clinical development.

Clinical Trials Arena on MSN · 13d

Novo Nordisk ramps up obesity fight, advances amycretin to Phase III

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and who are overweight. Following a positive end-of-Phase II meeting, Novo Nordisk shared that regulatory authorities have approved the therapy to proceed.

The Wall Street Journal on MSN · 3d

Novo Nordisk’s New Obesity Drug Beats Wegovy Weight Loss in Early Trial

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Fierce Biotech3d

Novo's injectable amycretin yet to hit weight loss plateau, suggesting Zepbound-beating potential

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Morningstar6d

Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess ...

PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed ...

BioSpace3d

Novo Leans on CagriSema’s Safety as Amycretin Moves Forward to Phase III

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or ...

13d

Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory ...

3don MSN

Experimental drug helps patients lose nearly a quarter of body weight in early trials

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Novo Nordisk falls as CagriSema obesity data shows no clear edge vs Zepbound

Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

pharmaphorum3d

ADA: Novo continues effort to rehabilitate CagriSema

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results